Suchergebnisse
Suchergebnisse:
23. Feb. 2022 · PHILADELPHIA, February 23, 2022 – Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Jeff, who co-founded the ...
23. Aug. 2023 · Spark Therapeutics, a US-based biotechnology company and a member of the Roche Group, began construction of a new Gene Therapy Innovation Center on Drexel University’s campus in Philadelphia, US, in February 2023. The facility will advance gene therapy manufacturing globally by bringing together experts for scientific advancements and serve ...
Browse featured videos, presentations, and more. Request Medical Information. Have a question about Spark products or therapeutic areas? You can ask it here. Call 1-866-647-7275. Talk with a Spark representative Monday through Friday, 8 AM to 8 PM ET.
Spark Therapeutics has built a leading integrated gene therapy platform as we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases including hemophilia, lysosomal storage disorders such as Pompe and Fabry, and neurodegenerative diseases.
12. Okt. 2017 · Novartis AG’s recently approved CAR-T cell therapy Kymriah (tisagenleceucel), which some classify as a gene therapy, costs $475,000 for a one-time treatment — a price below investor expectations. Spark’s therapy could cost much more, perhaps as much as $450,000 per eye according to an equity analyst from RBC Capital Markets.
17. Dez. 2021 · Spark's new center is now a sign of commitment from the biotech's pharmaceutical owner Roche, based in Switzerland but with an extensive network of labs under its banner. The planned $575 million investment is particularly notable, on par with major facility expansions from Eli Lilly , Pfizer and Amgen in recent years.
25. Feb. 2019 · Roche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy company Spark Therapeutics for $114.50 per share, corresponding to a total of around $4.8bn on a fully diluted basis. Spark Therapeutics focuses on the discovery, development and delivery of gene therapies for genetic disorders.
